Porton Pharma Solutions Ltd. engages in the manufacture and sale of small molecule active pharmaceutical ingredients, dosage forms, and biologics to the pharmaceutical companies in China, the United States, and Europe. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Porton Pharma Solutions and Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, production, and supply chain. The company was formerly known as Porton Fine Chemicals Ltd. and changed its name to Porton Pharma Solutions Ltd. in January 2018. Porton Pharma Solutions Ltd. was incorporated in 2005 and is headquartered in Chongqing, China.
Metrics to compare | 300363 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300363PeersSector | |
---|---|---|---|---|
P/E Ratio | −21.7x | 18.4x | −0.6x | |
PEG Ratio | 0.15 | 0.11 | 0.00 | |
Price/Book | 1.6x | 2.0x | 2.6x | |
Price / LTM Sales | 3.1x | 3.9x | 3.1x | |
Upside (Analyst Target) | 30.9% | 34.7% | 51.5% | |
Fair Value Upside | Unlock | 15.7% | 8.4% | Unlock |